IAG Appoints Dr. Christophe Berthoux a Chairman to the Board
LONDON, October 2, 2018
LONDON, October 2, 2018 /PRNewswire/ --
IAG, Image Analysis Group, the innovator in medical imaging solutions for drug development, announces the appointment of Dr. Christophe Berthoux as Chairman to the Board.
Dr. Berthoux joined IAG to develop the Company's people and growth strategies. Prior to this role, Dr. Berthoux served as the Chief Executive at Synexus Limited, which was acquired by Jaguar, a holding company of Pharmaceutical Product Development (PPD).
Dr. Berthoux has extensive experience in the international clinical trials sector and has worked both in the United States and Europe. He has spent all his 28-year career in the Clinical Research industry and served as a Chief Commercial Officer and Executive Vice President of Global Sales & Marketing for Charles River Laboratories International Inc., since September 2008.
Between 2010 and 2017, he served as CEO of multinational company Synexus, which was purchased by the private equity firm for £178m (approximately $258 million) in June 2016.
Prof. Richard Barker, who chaired the Board since 2014 and was instrumental in establishing IAG's Bio-Partnering, Strategy and Operations divisions, will remain on the Company's Board as a Non-Executive Director.
" We are pleased to welcome Christophe, " said Dr. Olga Kubassova, the CEO of IAG, "Christophe's extensive experience in leading global commercial teams and international business growth will be incredibly beneficial to IAG, as we look to drive successful growth and international expansion."
Dr. Berthoux was effective September 1, 2018.
ABOUT IAG, IMAGE ANALYSIS GROUP
IAG, Image Analysis Group, maximizes chances for bio-pharmaceutical companies to succeed in taking break-through therapies from phase I to the patient by bringing our robust and efficient cloud technology platform DYNAMIKA, Artificial Intelligence (AI) and Machine Learning (ML) driven data analytics and proprietary imaging biomarkers to enable faster fact-based decisions, optimized workflows and control over the study conduct and financial risks.
SOURCE IAG, IMAGE ANALYSIS GROUP